GAVI signs deal for diarrhea vax for world's poorest

After last week's rumors about a deal over HPV vaccines, the public-private partnership GAVI Alliance has signed a deal with GlaxoSmithKline ($GSK) and Merck ($MRK) for the rotavirus vaccines Rotateq and Rotarix. The deal cuts the price for the vaccines 67 percent, potentially saving $650 million, and means vaccines for 70 million children in the world's 40 poorest countries by 2016. A GSK spokesperson told Reuters that the company was glad to contribute to efforts against preventable diseases: "Rotavirus vaccine has demonstrated real-world, life-saving impact on reducing deaths. We have a chance here to collaborate in programs designed to protect millions of children." Press release | Article

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.